GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Tax Provision

KLTO (Klotho Neurosciences) Tax Provision : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Tax Provision?

Klotho Neurosciences's tax provision for the three months ended in Dec. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.


Klotho Neurosciences Tax Provision Historical Data

The historical data trend for Klotho Neurosciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Tax Provision Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Tax Provision
- - - -

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Klotho Neurosciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Klotho Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
13576 Walnut Street, 12th Floor, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.